| TAH Drug Code | ISEV |
|---|---|
| Indications | Infections of respiratory tract, GIT due to gm+ve & gm-ve bacteria. |
| Dosing | Trimethoprim-sulfamethoxazole (TMP-SMX)Adult and children > 12 years: 160/800-240/1200 mg (10-15 mL) twice daily. Children (6-12 years): 80/400 mg (5 mL) twice daily. Children (6 months-6 years): 40/200 mg (2.5 mL) twice daily. Children (6 weeks-5 months): 20/100 mg (1.25 mL) twice daily. Pediatric dose is calculated based on TPM 6 mg/kg/day and SMX 30 mg/kg/day. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment required |
| Contraindications | Liver parenchymal damage, blood dyscrasias; severe renal insufficiency. Pregnancy, lactation. Porphyria. |
| Adverse Effects | Allergic skin reactions; hallucinations, depression, apathy, nervousness. Arthralgia, myalgia. Neurologic reactions. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | LSUL |
|---|---|
| Indications | Acute exacerbations of chronic bronchitis, UTI & acute otitis media due to susceptible organisms; treatment & prophylaxis of P. carinii pneumonia; travelers?diarrhea due to susceptible strains of enterotoxigenic E. coli. |
| Dosing | Adults: trimethoprim/sulfamethoxazole 160/800-240/1200 mg (20-30 mL) BID for 7 days or 80/400 mg (10 mL) BID for 14 days. Children 6 weeks to 5 months: 20/100 mg (2.5 mL) BID; 6 months to 5 years: 40/200 mg (5 mL) BID; 6 years to 12 years: 80/400 mg (10 mL) BID. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment required |
| Contraindications | Hypersensitivity; megaloblastic anemia. |
| Adverse Effects | GI disturbances, allergic skin reactions (discontinue), folic acid deficiency; mild & transient hematological abnormalities; rarely, megaloblastic anemia, purpura, agranulocytosis. |
| Pregnancy | Unknown |
| Lactation | Unknown |
| More Info | UpToDate |
| TAH Drug Code | OMORC |
|---|---|
| Indications | Infection. |
| Dosing | Trimethoprim-sulfamethoxazole (TMP-SMX) Adult: 160/800 mg (2 tablets) orally 3 times daily. Children (6-12 years): 80/400 mg (1 tablet) orally 3 times daily. Reduce dose for children < 6 years of age. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment required |
| Contraindications | History of sulfonamide- or trimethoprim-induced immune thrombocytopenia. Hypersensitivity to sulfonamides or trimethoprim. Infants younger than 2 months of age. Marked hepatic damage. Megaloblastic anemia due to folate deficiency. |
| Adverse Effects | Common Dermatologic: Rash, Urticaria Gastrointestinal: Loss of appetite, Nausea, Vomiting Serious Cardiovascular: Cardiogenic shock, Prolonged QT interval, Torsades de pointes, Ventricular tachycardia Dermatologic: Drug reaction with eosinophilia and systemic symptoms, Erythema multiforme, Generalized exanthematous pustulosis, acute, Stevens-Johnson syndrome, Sweet's syndrome, Toxic epidermal necrolysis Endocrine metabolic: Hyponatremia Gastrointestinal: Clostridioides difficile infection, Associated diarrhea Hematologic: Agranulocytosis, Aplastic anemia, Disorder of hematopoietic structure, Neutropenia, Thrombocytopenia Hepatic: Hepatic necrosis, Fulminant Immunologic: Anaphylaxis Musculoskeletal: Rhabdomyolysis |
| Pregnancy | Human (and Animal) Data Suggest Risk |
| Lactation | No (Limited) Human Data - Potential Toxicity |
| More Info | UpToDate |